Terumo Corporation - ADR
TRUMY
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.41B
Close$
Earnings Call Q4 2024
May 16, 2024 - AI Summary
Terumo's FY '23 financial results showed record highs in sales revenue, operating income, and net income.
Revenue growth was 7% (excluding exchange rate effects), driven by growth in the U.S. and Europe.
Operating income grew by 14% (excluding exchange rate effects), outpacing sales growth.
-
Exclusive for Stockcircle Pro members
Sign up
$37.03
143.8% upside
Current Fair Value
143.8% upsideUndervalued by 143.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.41 Billion |
|---|---|
| Enterprise Value | $145.83 Billion |
| Dividend Yield | $0.18 (1.38%) |
| Earnings per Share | $97.47 |
| Beta | 0.23 |
| Outstanding Shares | 1,475,508,000 |
Return
| Return on Equity | 7.87% |
|---|---|
| Return on Assets | 5.51% |
| Return on Invested Capital | 7.84% |
Valuation & Multiples
| P/E Ratio | 21.52 |
|---|---|
| PEG | 31.5 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 0.16 |
| Enterprise Value to EBIT | 0.95 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 3 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$1.84 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$1.91 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▲ 0.00% |
|---|---|
| Total Invested | $790,492▲ 36.48% |
| Investors Holding | 70% |
ESG Score
No data
About Terumo Corporation
31,185 employees
CEO: Shinjiro Sato Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Ca...